Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Bristol-Myers Squibb

Eliquis, Opdivo sales offset decline in established brands

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb
1Q Revenues: $5.9 Billion (+14%)
1Q Earnings: $1.7 billion (+15%)
Comments: Eliquis sales were up 28% in the quarter to $1.9 billion. Opdivo sales were up 19% to $1.8 billion. Orencia sales were $640 million, up 8%. Yervoy sales were up 54% to $354 million. Baraclude sales were down 37% to $141 million. Other established brands sales were down 21% to $487 million. U.S. revenues increased 24% to $3.4 billion in the quarter. International revenues increased 2%. In April, the company announced plans to acquire Celgene Corporation, which is expected to close in the third quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters